A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT05609370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Study identification
- NCT ID
- NCT05609370
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Interventions
- Alcestobart Drug
- Tislelizumab Drug
- Bevacizumab or Bevacizumab biosimilar Drug
- Fluoropyrimidine (FP) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2023 (Actual)
- Primary completion
- May 23, 2025 (Actual)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Jul 23, 2026
2023 – 2026
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology, Llc | Anchorage | Alaska | 99508-2974 | — |
| Banner Md Anderson Cancer Center | Gilbert | Arizona | 85234-2165 | — |
| Helios Clinical Research | Cerritos | California | 90703 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067-2011 | — |
| Usc Norris Comprehensive Cancer Center (Nccc) | Los Angeles | California | 90089-1019 | — |
| UCLA Hematologyoncology | Los Angeles | California | 90095-3075 | — |
| Hoag Memorial Presbyterian | Newport Beach | California | 92663-4162 | — |
| Kaiser Permanente Northern California | Vallejo | California | 94589-2441 | — |
| Baptist Md Anderson Cancer Center | Jacksonville | Florida | 32207-8432 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | — |
| Baptist Health Lexington | Lexington | Kentucky | 40503-1466 | — |
| University of Kentucky Markey Cancer Center | Lexington | Kentucky | 40536-7001 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40217-1395 | — |
| Pontchartrain Cancer Center | Covington | Louisiana | 70433-7512 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121-2429 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110-1010 | — |
| St Vincent Frontier Cancer Center | Billings | Montana | 59102-6746 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169-3321 | — |
| Cancer Care Specialists | Reno | Nevada | 89511-2250 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87102-4517 | — |
| Perlmutter Cancer Center At Winthrop Oncology Hematology Associatesnyu Winthrop Hospital | Mineola | New York | 11501-3957 | — |
| Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health | New York | New York | 10016-2708 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Duke Cancer Center | Durham | North Carolina | 27710-2000 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920-1511 | — |
| Ut Southwestern Medical Center | Dallas | Texas | 75390-7208 | — |
| Ut Health San Antonio Mays Cancer Center | San Antonio | Texas | 78229-4427 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031-2171 | — |
| Cancer Care Northwest | Spokane Valley | Washington | 99216-1020 | — |
| Multicare Health System Institute For Research and Innovation | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05609370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05609370 live on ClinicalTrials.gov.